血友病中药代动力学指导与标准预防治疗的比较:系统综述与荟萃分析
该系统综述检索MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和EU临床试验注册库至2023年2月3日,纳入25项研究,其中仅2项随机对照试验和17项非随机研究设有标准预防治疗对照且后者偏倚风险高。对2项RCT的随机效应荟萃分析显示,出血结局(均值比1.15;95%CI 0.85-1.56)和因子消耗(均值比0.82;95%CI 0.58-1.18)均未达统计学显著。作者结论认为药代动力学指导较标准固定剂量预防治疗有临床获益的证据薄弱。
要点
- 仅2项RCT纳入荟萃分析,出血结局均值比1.15(95%CI 0.85-1.56)未达统计学显著。
- 因子消耗均值比0.82(95%CI 0.58-1.18),未达统计学显著。
- 支持药代动力学指导预防治疗优于标准固定剂量预防治疗的证据薄弱。
核心结论
- 文献中提示药代动力学指导较标准固定剂量预防治疗有临床获益的证据薄弱,主要见于缺乏同期对照、结局报告异质性、样本量小和高偏倚风险的非随机研究。
研究设计与样本
- 系统综述与荟萃分析,未限制纳入特定研究设计标签,纳入至少一个接受药代动力学指导预防治疗的独立队列臂的研究。
- 检索MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和EU临床试验注册库,自建库至2023年2月3日,由2名综述作者独立筛选题目、摘要和全文。
- 共纳入25项研究,其中仅2项随机对照试验和17项非随机研究设有标准预防治疗对照组。
- 对纳入的随机对照试验采用随机效应模型进行定量合成,非随机研究因偏倚风险高仅作定性呈现。
主要发现
- 检索日期2023年2月3日,共25项研究符合纳入标准。
- 仅2项RCT和17项非随机研究包含标准预防治疗对照组,非随机研究偏倚风险高,主要因前后对照设计和回顾性对照组。
- 2项RCT的随机效应荟萃分析显示,出血结局均值比1.15(95%CI 0.85-1.56),因子消耗均值比0.82(95%CI 0.58-1.18),均未达统计学显著。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 非随机研究缺乏同期对照。
- 结局报告存在异质性。
- 样本量小。
- 偏倚风险高,主要因前后对照设计和回顾性对照组。
- 2项RCT的荟萃分析对出血结局和因子消耗的结论仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With population pharmacokinetic (PK) modeling more readily available and PK-guided prophylaxis endorsed by current hemophilia guidelines, we conducted a systematic review to summarize current evidence in the literature. OBJECTIVES: To assess the efficacy of PK-guided compared with non-PK-guided prophylaxis. METHODS: We did not restrict inclusion to specific study design labels and included all studies consisting of at least one distinct cohort arm receiving PK-guided prophylaxis. We searched the following databases from inception to date of search: MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trial Register. Following title, abstract, and full-text screening conducted independently by 2 review authors, we summarized studies qualitatively and synthesized included randomized clinical trials (RCTs) quantitatively by fitting random-effects models. RESULTS: Search of databases on February 3, 2023, yielded 25 studies fitting our inclusion criteria. Of those, only 2 RCTs and 17 nonrandomized studies included a standard prophylaxis comparator group. Furthermore, risk of bias in the latter was substantial, primarily due to before-after study designs and retrospective comparator groups. Thus, nonrandomized studies were only presented qualitatively. A random-effects meta-analysis of the 2 identified RCT remained inconclusive with regards to bleeding outcomes (ratio of means, 1.15; 95% CI, 0.85-1.56) and factor consumption (ratio of means, 0.82; 95% CI, 0.58-1.18). CONCLUSION: Evidence in the literature suggesting a clinical benefit of PK-guided over standard fixed-dose prophylaxis was weak and mainly found in nonrandomized studies limited by lack of concurrent controls, heterogeneity in outcome reporting, small sample sizes, and high risk of bias.
引用
- Kraemmer D, Königsbrügge O, Moik F, et al. Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis. J Thromb Haemost. 2023. PMID: 37739039. doi:10.1016/j.jtha.2023.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。